Valeant Pharmaceuticals International, Inc., a multinational specialty pharmaceutical company,  and Bausch + Lomb, one of the best-known and most respected healthcare companies in the world, announced that the US Food and Drug Administration (FDA) has issued marketing clearance for Bausch + Lomb's newest frequent replacement silicone hydrogel contact lenses made with MoistureSeal Technology.  Representing the category's first new innovation in frequent replacement silicone hydrogel technology in seven years, this novel technology combines a breakthrough material with new manufacturing processes to produce a contact lens that offers superior comfort and vision.

"We are encouraged to receive this significant marketing clearance much sooner than originally expected," stated J Michael Pearson, chairman and chief executive officer of Valeant.  "When paired with Biotrue ONEday – our premium daily disposable contact lenses launched last year – we believe this new technology will begin to build an improved contact lens business by providing contact lens wearers with unsurpassed comfort and vision throughout the day."

MoistureSeal Technology is the latest vision care innovation from Bausch + Lomb building on the track record of breakthrough innovations including Biotrue ONEday contact lenses and Biotrue Multi-Purpose Solution.

Bausch + Lomb's frequent replacement silicone hydrogel contact lens is only available with a prescription from an eye care professional.

Valeant Pharmaceuticals International, Inc. is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology, and branded generics.